Les inscriptions sont closes
  • Fin d'inscription
  • Inscription close
  • Début du Cours
  • 17 sep 2015
  • Fin du cours
  • 01 nov 2015
  • Effort estimé
  • 02:30 h/semaine
  • Langue
  • Anglais

Vaccinology MOOC of Pasteur Institute and The Cnam

About the course / À propos du cours

The objective of this course is to offer an integrated overview of vaccinology, from public health and scientific data justifying the development of a vaccine, to its delivery to the populations in the context of industrialized and developing countries. Dedicated to candidates with a medical or scientific background who are interested in all aspects of vaccinology: medical and public health students, scientific Master II and PhD students (Immunology, Microbiology), physicians, pharmacists, veterinarians and other health professionals. The MOOC is composed of 31 lectures presenting historical aspects of vaccines, immunology and design of vaccines, basic principles of preclinical and clinical development, an update of vaccine development for the major infectious diseases, and the future challenges of vaccinology.

L'objectif de ce cours est d'offrir une vision intégrée de la vaccinologie, allant de la santé publique et des données scientifiques qui justifient le développement d'un vaccin, jusqu'à sa distribution aux populations dans le contexte des pays industrialisés et en développement. Destiné aux personnes ayant une formation médicale ou scientifique qui s'intéressent à tous les aspects de la vaccinologie: étudiants en médecine et en santé publique, Masters scientifiques et doctorants (immunologie, microbiologie), médecins, pharmaciens, vétérinaires et autres professionnels de santé. Le MOOC est composé de 31 séquences présentant les aspects historiques des vaccins, l'immunologie et la conception des vaccins, les principes de base du développement préclinique et clinique, une mise à jour du développement des vaccins pour les principales maladies infectieuses, et les futurs défis de la vaccinologie.

Format :

This MOOC is organized in 6 modules over a time period of 6 weeks. Each module consists of 5/6 video sequences of 10 minutes length on average, followed by two questions to help learners to update their understanding. For each sequence, discussions are open on the forum. The main questions addressed on the forums will be answered weekly in live by hangouts. The videos are in English subtitled in French.
Ce Mooc est organisé en 6 modules sur une durée de 6 semaines. Chaque module se compose de 5/6 séquences vidéos, de 10 minutes chacune en moyenne, suivies de deux questions qui permettent aux apprenants de faire le point sur leurs acquis. Pour chaque séquence, des discussions sont ouvertes sur le forum. Les retours hebdomadaires aux principales questions posées sur les forums, se feront en direct par hangout. Les vidéos sont en anglais sous-titrés en français.

Evaluation :

Weekly tests plus a final QCM test will allow obtaining a certification of successful attending to the course.
Des épreuves hebdomadaires et une épreuve terminale de type QCM, permettent l’obtention de l’attestation de suivi avec succès.

WHO SHOULD ATTEND THIS MOOC ? /  A QUI S'ADRESSE CE MOOC ?

This Mooc is dedicated to doctors, pharmacists, researchers, students, nurses or other staff of public or private hospitals, staff of the pharmaceutical industry or of public health services.
Ce Mooc est destiné aux médecins, pharmaciens, chercheurs, étudiants, infirmiers et autres personnels des hôpitaux publics ou privés, au personnel de l'industrie pharmaceutique ou des services de santé publics.

Prerequisites are / Les prérequis sont :

Background in microbiology, immunology, public health / Connaissances en microbiology, immunology, santé publique.

Course staff /Équipe pédagogique

Armelle Phalipon

Armelle Phalipon is a microbiologist leading a group within the Molecular Microbial Pathogenesis Unit, INSERM U786, at the Institut Pasteur, Paris, France. Working in the field of diarrheal diseases, her team is interested in deciphering the cross-talks between enteropathogenic bacteria and the host immune system. The main current studies aim at deciphering how Shigella, the bacterium responsible for bacillary dysentery, impacts on the development of the short-term, poorly effective protective immunity elicited in response to infection. Armelle Phalipon has a long-standing interest in combining fundamental and applied research. Indeed, in collaboration with Dr. Laurence Mulard (Institut Pasteur, Paris), she has designed a new type of Shigella vaccine candidate that will enter a phase 1 clinical trial in 2016 for proof of concept in humans. She is co-founder and co-director with Frédéric Tangy of the first International Vaccinology Course launched at the Pasteur Institute in 2008.

Frédéric Tangy

Frédéric Tangy, PhD, Dr.Sc., Director of Research at CNRS, is the head of the Viral Genomics and Vaccination Research Unit at Institut Pasteur, Paris (CNRS UMR-3569). After his PhD in 1980 and his Dr. Sc. in 1984 at Paris VI University he made his career as a virologist first at CNRS then at Institut Pasteur. He is co-director of the international Vaccinology course of Institut Pasteur, vice-president of the Scientific Council of Institut Pasteur, and member of ASM, ESGT, IAS, SFI. He is the author of 110 publications in international scientific journals and 19 international patents. In the recent years, he has developed two research programs: 1) generation of polyvalent viral attenuated vaccines based on a vector derived from measles vaccine. This project extends from the design of antigens and generation of recombinant vectors, to preclinical and clinical development in the field of HIV, dengue, chikungunya and malaria vaccines. 2) The second project investigates the interactions between viral and host proteins in a systematic way using functional genomic approaches such as high-throughput cloning, yeast two-hybrid, deep sequencing and high-throughput drug screening. This project aims at understanding at a molecular level the interactions between viral and host proteins and RNA in the field of paramyxoviruses. These observations lead to identify new drug targets and new determinants of pathogenicity/attenuation.

With the participation of / Avec la participation de :

Richard ASPINALL DSc FRCP(Edin) FRCPath Academy of Health and Wellbeing, Anglia Ruskin university
Deborah ATHERLY, Director, Health Economics and Outcomes Research PATH, Seattle USA
Brigitte AUTRAN, CIMI (Centre de recherches Immunologie & Maladies Infectieuses) Université Pierre et Marie Curie Hôpital Pitié-Salpétrière Paris France
Michel BEURRET, Scientific Director Bacterial Processes & Analytics, Janssen
Maria Elena BOTTAZZI, PhD FASTMH, Associate Dean National School of Tropical Medicine Baylor College of Medicine Houston, TX USA
Stephen BROWN PhD, Executive Director BE Vaccines, Nantes, France
Joël CALMET, Sanofi Pasteur
Diana CHANG BLANC, World Health Organization Expanded Programme on Immunization Programme Operations Team Manager
Behazine COMBADIERE, Director of Research, Inserm, Centre d’Immunologie et des Maladies Infectieuses Cimi-Paris, France
Mark FLETCHER Senior Director, Pfizer, Paris
Giuseppe DEL GIUDICE, MD,PhD, GlaxoSmithKline, Research Center Siena, Italy
Francis DELPEYROUX, WHO Collaborative Centre of Research on Enteroviruses & Viral Vaccines. Biology of Enteric Viruses Unit. INSERM U994 – INSTITUT PASTEUR
Othmar G ENGELHARDT, Principal Scientist National Institute for Biological Standards and Control a centre of the Medicines and Healthcare products Regulatory Agency
Mark FLETCHER, Senior Director, Pfizer, Paris
Guido GRANDI, Prof. Microbiology and Clinical Microbiology, University of Trento, Trento, Italy
Marie-Lise GOUGEON, Antiviral Immunity, Biotherapy and Vaccine Unit Institut Pasteur
Nicole GUISO ,Molecular Prevention and Therapy of Human Diseases Research Unit French National Center of Reference for Pertussis and other bordetelloses and for toxinogenic corynebacteria Institut Pasteur, Paris, France
Karin HARDT, PhD, Director, Worldwide Vaccinology, Vaccine Education and Medical Training GSK Vaccines
Ruth A. KARRON, M.D., Professor and Director, Center for Immunization Research Bloomberg School of Public Health Johns Hopkins University
Daniel LÉVY-BRUHL, French Institute for Public Health Surveillance
David JM Lewis MD, Imperial College, London
Arnaud MARCHANT,Institute for Medical Immunology Université Libre de Bruxelles
Flor MUNOZ, MD, Associate Professor of Pediatrics Baylor College of Medicine Houston, Texas
Stanley PLOTKIN, Professor Emeritus of Pediatrics University of Pennsylvania
Audino PODDA, Vaccines Institute for Global Health GSK – Siena Italy
Rino RAPPUOLI, Coordinator of ADITEC European project and Chief Scientist, GSK Vaccines
Zarifah HUSSAIN REED CEO and Chief Medical Officer Vac4All
Rafick-Pierre SEKALY, Professeur Departement de Pathologie Case western Reserve University
Steffen STENGER, Medical Microbiology and Infection Control, University Hospital Ulm, Germany
Daniel TARANTOLA, MD, Former Director of the WHO Programme on Immunization, Vaccines and Biologicals WHO Headquarters, Geneva
Angus THOMSON, Director, Vaccination Advocacy, Sanofi Pasteur
Timo VESIKARI, Vaccine Research Center University of Tampere Finland
Peter J. WHITE, Public Health England and Imperial College London, UK

Course Syllabus / Plan du cours

MOOC Vaccines

Week 1

  • Introduction (C. Bréchot)
  • Program presentation (A. Phalipon & F. Tangy)

History-Basics

  • History of vaccines including IP (S. Plotkin)
  • Smallpox eradication (D. Tarantola)
  • Polio eradication (F. Delpeyroux)
  • Modeling in vaccinology (P. White)
  • Antigen discovery (G. Grandi)

Week 2
Basics suite

  • Immune memory of vaccines (RP. Sekaly)
  • Vaccines for pregnant women (F. Munoz)
  • Vaccines for neonates (A. Marchant)
  • Correlates of protection (M. Fletcher)
  • Adjuvants (G. del Guidice)
  • Delivery of vaccines (B. Combadière)


Week 3

Basics/suite

  • On the importance of maintaining vaccine coverage (D Levy-Bruhl)
  • Epidemiology post vaccination: pertussis vaccine example (N. Guiso)

Preclinical and clinical development

  • GMP production (S. Brown)
  • Immuno-monitoring (ML. Gougeon)
  • Phase I/II clinical trials (D. Lewis)
  • Phase III clinical trials (A. Podda)

Week 4
Recent success / New Vaccines made recently available

  • Success of glycoconjugate vaccines (M. Beurret)
  • Rotavirus vaccines (T. Vesikari)
  • HPV vaccines (K. Hardt)

Improving existing vaccines

  • Influenza vaccines (O. Engelhardt)
  • TB vaccines (S. Stenger)

Week 5
Vaccines remaining to be developed and implemented

  • RSV vaccines (R. Karron)
  • HIV vaccines (B. Autran)
  • Malaria vaccines (Z. Reed)
  • Vaccines against neglected parasites and worms (ME. Bottazzi)

Week 6

Future challenges

  • Innovation in future vaccines (R. Rappuoli
  • Vaccines for the elderly (R. Aspinal))
  • Vaccine economics (D. Atherly)
  • Globalization of vaccine production (J. Calmet)
  • Vaccine implementation on the field (D. Chang Blanc)
  • Vaccine perception (A. Thompson)

TERMS OF USE / Conditions d'utilisation

  • Course: Creative Commons License BY NC ND. The user must include the name of the author, it can exploit the work except in a commercial context and can not make any changes to the original work.
    Du cours : licence Creative Commons BY NC ND. L’utilisateur doit mentionner le nom de l’auteur, il peut exploiter l’œuvre sauf dans un contexte commercial et il ne peut apporter de modifications de l’œuvre originale.
  • Content produced by users: restrictive license. Your production is on your intellectual property and therefore can not be reused.
    Du contenu produit par les internautes : licence restrictive. Votre production relève de votre propriété intellectuelle et ne peut donc pas être réutilisée.